BALLERUP, Denmark & BANGKOK, Thailand–(BUSINESS WIRE)–DKSH Business Unit Healthcare, a premier partner for healthcare companies looking to grow their business in Asia and beyond, has partnered with LEO Pharma to deliver high-quality dermatology therapeutics and thrombosis to patients across Asia.
Partnering in Hong Kong, Malaysia, Singapore, Taiwan, Thailand, Vietnam and the Philippines, the two companies seek to consolidate brand presence, grow market share and ultimately improve patient health outcomes in the region. Skin diseases can cause serious physical and social discomfort to millions of patients around the world, while thrombosis can affect anyone, regardless of age, race, gender and ethnicity.
DKSH will support LEO Pharma by creating dedicated sales and marketing teams on the ground in Asia and managing the logistics and distribution of products in these markets. The company’s experienced teams and extensive distribution network will ensure that LEO Pharma products reach modern commerce, traditional commerce, hospitals, clinics and other medical channels, as well as patients in need throughout the region.
LEO Pharma is a global company dedicated to improving standards of care for the benefit of people with skin conditions, their families and society. With decades of research and development to advance the science of dermatology, LEO Pharma now offers a wide range of innovative treatments and therapies for all severities of skin diseases as well as thrombosis.
Khalid Aouidat, Vice President, Head of Business Operations Southeast Asia at LEO Pharma commented: “At LEO Pharma, we are committed to changing the standards of care for people with skin conditions by providing innovative new treatments and making them easily accessible. Supporting this ambition, we are delighted to partner with DKSH. Their experience and strong regional presence in Asia, along with their marketing and sales expertise, should help further strengthen the LEO Pharma brand and its continued growth.
Bijay Singh, Head of Healthcare Business Unit at DKSH, said: “We are committed to enriching people’s lives and improving healthcare for all. The partnership with LEO Pharma reinforces our ambition to become the preferred partner for customers to help patients in Asia have better access to quality and innovative products and solutions. As we stimulate their growth in the region, LEO Pharma can focus on the research and development of products and solutions for people with skin problems.
About LEO Pharma
LEO Pharma is a global company dedicated to improving standards of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority-owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advancing the science of dermatology, and today the company offers a wide range of therapies for all severities of skin disease. sickness. LEO Pharma is headquartered in Denmark and has a global team of 5,200 people, serving millions of patients around the world. In 2021, the company achieved net sales of 1,339 million euros. www.leo-pharma.com
DKSH’s goal is to enrich people’s lives. For more than 150 years, we’ve been growing businesses in Asia and beyond across our Healthcare, Consumer Goods, Performance Materials and Technology business units. As a leading provider of market expansion services, we offer sourcing, market analysis, marketing and sales, e-commerce, distribution and logistics, and after-sales services. DKSH is a member of the United Nations Global Compact and adheres to its principle-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Healthcare Business Unit distributes pharmaceutical, consumer healthcare and over-the-counter (OTC) as well as medical products. devices. With approximately 7,920 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec